الفهرس 
AcknowledgmentsOnly 14 pages are availabe for public view
 |  | from | 50 |  |  |
| | | from | 50 | | |
Abstract
Inflammatory bowel disease (IBD) is characterized by chronic inflammation along the gastrointestinal
tract. For IBD effective treatment, developing an orally administered stable drug delivery system capable
of targeting inflammation sites is a key challenge. Herein, we report pH responsive hyaluronic (HA)
coated Eudragit S100 (ES) nanoparticles (NPs) for the targeted delivery of budesonide (BUD) (HA-BUDES-
NPs). HA-BUD-ES-NPs showed good colloidal properties (274.8 ± 2.9 nm and − 24.6 ± 2.8 mV) with
high entrapment efficiency (98.3 ± 3.41%) and pH-dependent release profile. The negative potential
following incubation in simulated gastrointestinal fluids reflected the stability of HA coat. In vitro studies
on Caco-2 cells showed HA-BUD-ES-NPs biocompatibility and enhanced cellular uptake and antiinflammatory
effects as shown by the significant reduction in IL-8 and TNF-α. The oral administration of
HA-BUD-ES-NPs in an acetic acid induced colitis rat model significantly mitigated the symptoms of
IBD, and improved BUD therapeutic efficacy compared to drug suspension. This was proved via the
improvement in disease activity index and ulcer score in addition to refined histopathological findings.